BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers.
Board of Directors
BerGenBio is a privately owned company with investors from Norway and UK.
Notice of GM
Annual Report 2016
Instructions for the Nomination Committee
Proposal from the Nomination Committee
Statement from the board of directors pursuant to section 6-16a of the public limited liability companies act
Påmeldings- og fullmaktsskjema
Registration and Proxy form
Minutes AGM 22nd March 2017